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Abnormal mitochondrial function is a key process in the pathogenesis of Parkinson’s disease (PD). 
The central pore-forming protein TOM40 of the mitochondria is encoded by the translocase of outer 
mitochondrial membrane 40 homologue gene (TOMM40). The highly variant ‘523’ poly-T repeat is 
associated with age-related cognitive decline and age of onset in Alzheimer’s disease, but whether 
it plays a role in modifying the risk or clinical course of PD it yet to be elucidated. The TOMM40 ‘523’ 
allele length was determined in 634 people with PD and 422 healthy controls from an Australian 
cohort and the Parkinson’s Progression Markers Initiative (PPMI) cohort, using polymerase chain 
reaction or whole genome sequencing analysis. Genotype and allele frequencies of TOMM40 ‘523’ 
and APOE ε did not differ significantly between the cohorts. Analyses revealed TOMM40 ‘523’ allele 
groups were not associated with disease risk, while considering APOE ε genotype. Regression analyses 
revealed the TOMM40 S/S genotype was associated with a significantly later age of symptom onset 
in the PPMI PD cohort, but not after correction for covariates, or in the Australian cohort. Whilst 
variation in the TOMM40 ‘523’ polymorphism was not associated with PD risk, the possibility that 
it may be a modifying factor for age of symptom onset warrants further investigation in other PD 
populations.
Parkinson’s disease (PD) is increasingly known as a multifaceted neurodegenerative disorder with a heterogene-
ous and burdensome symptom presentation and progression. Abnormal or deficient mitochondrial functioning 
is widely implicated as a key process in the selective neuronal death and pathogenesis of PD. Mitochondrial 
dysfunction, resulting in a loss of electron transport chain (ETC) efficiency or decline in ATP-synthesising 
capacity, appears to elicit dopaminergic cell death via a number of mechanisms, including reactive oxygen 
species(ROS)—generation, impaired ATP production and disrupted calcium  homeostasis1,2. The pivotal role 
of mitochondrial dysfunction in PD is supported by several parkinsonism-causing toxins, genetic mutations 
and retrotransposon  insertions3,4, which specifically impair mitochondrial function. Insights from these toxins 
and mutations imply that mitochondrial dysfunction in the pathogenesis of PD can arise from a wide array of 
biological processes, such as bioenergetic disturbances, nuclear and mitochondrial DNA mutations, impaired 
fusion and fission, defective mitophagy, and abnormal morphology and  size5. For example, a significant cause 
of mitochondrial dysfunction in PD is the inhibition of mitochondrial complex I, an ETC defect that leads to 
severe oxidative stress and ROS- and caspase- mediated dopaminergic cell  death5. Notably, the latter impairment 
is a major pathological feature of PD induced by familial PTEN-induced kinase 1 (PINK1), alpha-synuclein 
(SNCA) and Daisuke-Junko-1 (DJ-1) gene mutations or the toxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine 
(MPTP)3. Thus, mitochondrial dysfunction is thought to cause neuronal stress and degeneration, eventuating 
in this neurodegenerative disease, PD.
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The translocase of outer mitochondrial membrane 40 homologue (TOMM40) gene encodes the pore-forming 
subunit (TOM40) of the protein-transport channels in the mitochondrial outer membrane, thus playing a fun-
damental role in mitochondrial  functioning6. The TOM40 protein facilitates the import of approximately 1500 
externally synthesised proteins and peptides into the mitochondria, and plays a key role in the mitophagy deg-
radation  pathway7,8. Altered or abnormally functioning TOM40, mediated by genetic changes or atypical protein 
expression, is thought to contribute to mitochondrial dysfunction and protein accumulation in Alzheimer’s 
disease (AD) and  PD8. This may occur through different mechanisms: (1) mitochondrial import impairment, 
which may prevent essential proteins and peptides from reaching their designated mitochondrial targets, or allow 
unwanted and mutant proteins to aggregate in the mitochondria; or (2) mitophagy disruption, which may enable 
damaged and malfunctioning mitochondria to accumulate. Given evidence for mitochondrial dysfunction in 
PD, genetic variants affecting TOMM40 expression may have risk and disease-modifying effects.
Downstream of TOMM40 is apolipoprotein E (APOE), which is in a region of strong linkage disequilibrium 
(LD), or non-random association, with TOMM40  variation9–11. Though the extent to which common variants in 
TOMM40 can have APOE-independent effects on disease risk or disease-modifying effects remains uncertain, 
polymorphisms in TOMM40 have been independently associated with a range of primarily cognition-based 
neurodegenerative diseases, including AD, frontotemporal dementia and dementia with Lewy bodies, as well as 
non-pathological  ageing8,12–15. One of these variants is situated in intron 6 of TOMM40 and is a homopolymer 
of repeating thymine (T) nucleotides known as rs10524523 or ‘523’9,16. The ‘523’ variant is polymorphic, with 
lengths that vary from 11 to 39 T residues in  Caucasians9,17. To better categorise and describe this diverse struc-
tural variant, three allelic groups for the homopolymer have been established previously, according to the number 
of constituent T residues: ‘Short’ (S, T ≤ 19), ‘Long’ (L, 20 ≤ T ≤ 29) and ‘Very Long’ (T ≥ 30)9,17,18. Although the 
functional effects of the ‘523’ variation are mostly unknown, increasing length of the poly-T repeat is thought to 
increase TOMM40  expression19,20. Therefore, the effect of the TOMM40 ‘523’ variant and altered TOM40 protein 
levels may contribute to mitochondrial dysfunction in  PD16,21. While a vast number of published studies report 
conflicting roles of the various TOMM40 ‘523’ variant lengths in AD and ageing  populations22–26, there have only 
been two previous studies within PD cohorts with differing findings. The first was a study of a relatively large 
Polish PD cohort which found no significant associations between TOMM40 ‘523’ and PD risk or age of  onset27. 
Subsequently, a significant overrepresentation of the L/VL ‘523’ genotype was reported in a Swedish PD cohort 
compared to healthy controls, though it should be noted that these findings are yet to be published in  full28. Thus, 
with conflicting findings in these two European cohorts, further investigation in other populations is required.
Due to the essential role of TOMM40 in mitochondrial import and mitophagy, both plausible sources of PD-
causing mitochondrial dysfunction, the ‘523’ variant in TOMM40 is therefore a potential risk factor and disease 
modifier in PD. This study investigated the distribution of ‘523’ alleles and their association with disease risk and 
age of symptom onset in two independent PD cohorts, one Australian and one international (the Parkinson’s 
Progression Markers Initiative, PPMI), using PCR-based and whole genome sequencing approaches.
Methods
Cohorts. The first cohort comprised of 235 home-based people with PD (PwP) and 231 healthy controls of 
European heritage from the Perron Institute for Neurological and Translational Science PD Database, as previ-
ously  reported29. Clinical and demographic data, including the age of symptom onset, were recorded in the data-
base. All PwP were examined by a movement disorder neurologist prior to inclusion in the study for verification 
of the diagnosis in accordance with the UK Brain Bank criteria for idiopathic PD and reported no family history 
of  PD30, while healthy controls were confirmed to have no history of any neurological disorders. This study 
was approved by the Sir Charles Gairdner Hospital Human Research and Ethics Committee (Approval number 
2006/073). Written informed consent was obtained from all participants, in accordance with the Australian 
National Health and Medical Research Council research guidelines.
The second cohort was derived from the international Parkinson’s Progression Markers Initiative (PPMI) data-
base (available at http:// www. ppmi- info. org/ data). This cohort comprised of 368 PwP and 172 healthy controls, 
and only individuals of European heritage were included in order to reflect the composition of the Australian 
cohort.
DNA extraction. In the Australian cohort, DNA was extracted from either blood samples or buccal swabs. 
Participant buccal samples were collected by a trained researcher using Isohelix DNA/RNA Buccal Swabs (Cell 
Projects Ltd, Kent, U.K.) and stored until DNA extraction. Alternatively, blood was collected from the medial 
cubital vein. DNA was extracted and purified from these samples using QIAamp DNA mini kits (Qiagen Pty 
LTD., Victoria, Australia), according to the manufacturer’s protocol. DNA concentration was determined using 
absorbance readings calculated by a NanoDrop One Microvolume UV–Vis spectrophotometer (Thermo Fisher 
Scientific Australia Pty LTD., Victoria, Australia).
Genotyping of TOMM40 ‘523’ using PCR and fragment analysis. PCR-amplification of the ‘523’ 
variant in the Australian cohort was completed using fluorescently labelled primers, as previously  described19. 
The forward primer sequence was 5′-/6-FAM/-TGC TGA CCT CAA GCT GTC CTC-3′ and the reverse primer 
was 5′-GAG GCT GAG AAG GGA GGA TT-3′, synthesized by Integrated DNA Technologies Pty Ltd (IDT, Iowa, 
USA). Endpoint PCR was performed using 5 μL of 5 × MyFi Reaction Buffer (including 1 mM dNTPs and 3 mM 
MgCl2; Bioline, NSW, Australia), 1 μL of MyFi DNA Polymerase (Bioline), 0.2 μL of each forward and reverse 
primer (20 μM) (IDT), 0.25 μL of 1% dimethylsulfoxide (DMSO; Sigma), 50 ng of genomic DNA, and 11.35 μL 
of dH2O (Baxter Healthcare); to a final volume of 25 µL. Optimised PCR conditions were as follows: 1 cycle 
at 94 °C for 3 min, 27 cycles at 94 °C for 15 s, annealing at 65 °C for 20 s and extension at 70 °C for 30 s, and 1 
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cycle at 70 °C for 5 min. Applied Biosystems SimpliAmp Thermal Cyclers (Thermo Fisher Scientific, MA, USA) 
were used for endpoint PCR cycling. Post PCR products were stored at 4 °C until capillary fragment separation, 
which was conducted by the Australian Genome Research Facility (AGRF, WA, Australia). Electropherograms 
were analysed using Peak Scanner Software (v1.0; Thermo Fisher Scientific). ‘523’ allele lengths were determined 
according to a previously established method by Linnertz et al.19. Briefly, the highest intensity peak(s) in each 
peak cluster between 160–190 bp were identified and sized, and 150 bp (accounting for flanking regions and 
primers) was subtracted from the peak sizes to determine poly-T allele lengths. Alleles were grouped using the 
convention established by Roses et al.9: Short (S, T ≤ 19), Long (L, 20 ≤ T ≤ 29) and Very Long (VL, T ≥ 30).
Genotyping of TOMM40 ‘523’ using Whole Genome Sequencing. Whole genome sequencing 
(WGS) data were obtained from the PPMI database (available at http:// www. ppmi- info. org/ data) in binary align-
ment map (BAM) format that had been aligned to the human reference genome GRCh38 using the Burrows-
Wheeler transform alignment  algorithm31. Resultant BAM files were analysed using the Integrative Genomics 
 Viewer32 in order to calculate the length of the poly-T repeat, as previously  demonstrated33. Alleles were grouped 
using the convention established by Roses et al.9: Short (S, T ≤ 19), Long (L, 20 ≤ T ≤ 29) and Very Long (VL, 
T ≥ 30).
APOE ε genotyping. Genotyping of APOE ε were determined using the single nucleotide polymorphism 
(SNP) and PCR-restriction fragment length polymorphism (PCR–RFLP) analyses. APOE ε2/ε3/ε4 genotypes 
were determined by sequencing two SNPs (rs429358 and rs7412) using the MassARRAY system (Agena, Bio-
sciences) at the Australian Genome Research Facility (AGRF; Queensland, Australia)34. For PCR–RFLP analyses, 
endpoint PCR reactions were prepared to a final volume of 10 µl using primer sequences previously  described35. 
Reactions contained 7.2 µl  dH2O (Baxter Healthcare, NSW, Australia), 2 µl MyFi reaction buffer (Bioline, NSW, 
Australia,), 0.05 µl MyFi DNA polymerase (Bioline, NSW, Australia), 0.375  µl forward and, 0.375  µl reverse 
primer (Integrated DNA Technologies, Iowa, USA) at 200 ng/µl, and 25 ng DNA. The PCR amplification pro-
tocol followed, being an initial hold temperature of 95 °C for 4 min 30 s and 35 cycles of denaturation at 95 °C 
for 30 s, annealing 60 °C for 30 s and extension at 72 °C for 1 min 30 s. Restriction enzyme reactions were pre-
pared to a final volume of 20 µl, containing 6.3 µl  dH2O (Baxter Healthcare, NSW, Australia), 0.2 µl acetylated 
BSA (Promega, WI, USA), 2 µl C buffer (Promega, WI, USA), 0.5 µl Hhal (Promega, WI, USA) and 10 µl PCR 
product. Reactions were incubated for 4 h at 37 °C prior to polyacrylamide gel fractionation. Restriction enzyme 
digested products were fractionated on 12% (w/v) 29:1 polyacrylamide gel (BioRad, CA, USA) in 1 × TBE. Elec-
trophoresis fragment separation was performed at 100 V for 3 h on the DCode Universal Mutation Detection 
System (BioRad, CA, USA). Gels were stained in 1 × TBE containing SYBR Gold nucleic acid gel stain (Thermo 
Fisher Scientific, MA, USA) for 4 min before visualization using a BioRad Chemidoc MP Imaging System. APOE 
ε genotype data relating to the PPMI cohort was obtained from the online database (available at www. ppmi- info. 
org/ data).
Statistical methods. The Australian and PPMI cohorts were analysed separately, and together, using IBM-
SPSS software (version 26, IBM Corporation). A significant nominal p-value of < 0.05 was employed for all sta-
tistical tests. Variables were described using mean and standard deviation (in brackets, SD), or frequency and 
percent (in brackets, %), as appropriate. Normality was assessed and subsequent clinical characteristics were 
analysed using Independent Samples T-Test, Mann–Whitney U, or Chi-square, as appropriate. For cross-sec-
tional analysis, Chi-square, stratified Mantel–Haenszel tests and binary logistic regression models were used to 
evaluate the association between TOMM40 ‘523’ genotypes and risk of PD in the Australian and PPMI cohorts. 
Binary logistical regression models were run both with and without correction for the APOE ε4 status (being 
grouped as zero, one or two ε4 allele(s)) and patient sex. Analysis was also run considering all combinations of 
‘523’ length category and APOE ε genotype, to examine for interactive effects without a priori assumptions. The 
aforementioned analyses were performed separately in the PPMI and Australian cohorts, and after combination 
of the cohorts. Following this, binary logistic models were carried out when considering populations of APOE 
ε3/ε3 carriers only, as previously examined in this fashion and stated as a requirement for replication  studies13.
Generalised linear models (GLMs) were also constructed in order to study the interaction of TOMM40 on 
age of disease onset, correcting for APOE ε allele status and sex. Again, GLMs were carried out when considering 
populations of APOE ε3/ε3 carriers only. Residual plots were examined for all models and no violations were 
noted. Correction for multiple comparisons was conducted using Bonferroni pairwise comparisons, where 
appropriate.
Subsequently, the load combination of TOMM40 ‘523’ S allele carrier status (being S/S genotype, carriage of 
one S allele, and non-carriage of the S allele) and APOE ε4 status (the genotype ε4/ε4, carriage of one ε4 allele 
and non-carriage of the ε4 allele) were combined to produce 5 groups. Mean comparisons were then analysed 
using the Kruskal–Wallis one-way analysis of variance and univariate GLMs. This analysis was repeated in the 
combinations of TOMM40 ‘523’ S allele carrier status and APOE ε2 status, and TOMM40 ‘523’ VL allele carrier 
status and APOE ε4 status.
Finally, Kaplan–Meier curves for age at PD symptom onset were estimated, stratified by TOMM40 ‘523’ 
genotype as well as both the TOMM40 ‘523’ and APOE genotype. To compare the survival curves, the log rank 
test was applied, placing weight on longer survival  periods36,37. Allelic stratification by TOMM40 ‘523’ was also 
run using Kaplan–Meier analysis. Additionally, all distributions of ages at onset adjusting for sex were compared 
via Cox proportional hazard regression models.
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Results
Cohort information. A summary of the cohorts included in this study is presented in Table 1. The Austral-
ian cohort (n = 466) consisted of 231 controls and 235 PwP. Both the controls and PwP of this cohort consisted 
of more males (63.6% and 63.8%, respectively), and were aged 63.9 and 65.9 years, respectively. The PPMI cohort 
(n = 540) was comprised of 172 controls and 368 PwP. This cohort was similarly dominated by males (65.7% of 
controls, 65.5% PwP), with controls having a mean age of 61.6 years and those with PD having a mean age of 
61.8 years.
TOMM40 ‘523’ and APOE ε genotyping and distribution. In the Australian cohort, TOMM40 ‘523’ 
genotyping was obtained following optimisation of a PCR-based assay, with representative electropherograms 
presented in Supplementary Fig. 1. Genotyping of the TOMM40 ‘523’ variant in the PPMI cohort was com-
pleted using a WGS method, previously reported as an alternative method to fragment analysis and Sanger 
 sequencing33. The distribution of the ‘523’ alleles in PwP compared to healthy controls for both cohorts are 
presented in Fig. 1. Following prior literature, allele sizes were used to bin samples into Short (S, T ≤ 19), Long 
(L, 20 ≤ T ≤ 29) and Very Long (VL, T ≥ 30)  groups9 (Supplementary Table 1). APOE ε genotypes of the Austral-
ian cohort were further validated using PCR–RFLP, with representative samples ε2/ε3, ε2/ε4, ε3/ε3 and ε3/ε4 
presented in Supplementary Fig. 2. APOE ε genotype and allele groupings for both cohorts exhibited similar 
distributions, however there was an absence of individuals with the ε2/ε2 genotype in the Australian cohort (see 
Supplementary Table 2).
Both groups consisted of individuals with self-reported of European heritage, though country of origin 
information was not available for all cases. To determine whether cohorts could be appropriately combined, 
Levene’s Test for Equality of Variances was used to compare the ‘523’ distribution and no significant difference 
was observable (F = 1.772, p = 0.183). Each distribution was also compared to distributions on Webstr data-
base, similarities were seen between the current study cohorts and both the Gtex (predominantly European 
self-reported ancestry) and 1000 genomes European distributions. Thus, the current cohort were considered 
reflective of a population of European descent and the two cohorts could be combined to increase the sample 
size and power to detect ‘523’ effect.
TOMM40 ‘523’ not associated with PD risk. As there were no significant differences in TOMM40 allele 
distributions between cohorts, case–control analyses were completed in both individual cohorts and in a com-
bined cohort. When examined genotypically, the TOMM40 ‘523’ variant was not significantly associated with 
the risk of PD in either the Australian cohort (χ2 = 1.455, p = 0.918), or the PPMI cohort (χ2 = 1.806, p = 0.875), 
or when cohorts were combined (χ2 = 3.471, p = 0.628). Moreover, when combined, allelic distribution of the S 
(44.6% Vs 44.7%, Supplementary Table 1), L (11.8% Vs 13.9%, Supplementary Table 1) and VL (43.6% Vs 41.4%, 
Supplementary Table  1) binned groups was not significantly different between PD and controls (χ2 = 0.003, 
p = 0.953; χ2 = 0.723, p = 0.395; χ2 = 0.149, p = 0.699; respectively). Analysis considering all combinations of ‘523’ 
genotypes and APOE ε genotypes also failed to show any significant differences between PD and control groups. 
As with prior findings, analysis utilising stratified Mantel–Haenszel tests did not find significant differences.
Binary logistic regression models were analysed comparing each genotype or allele to all other genotypes or 
alleles (Table 2). Genotypically, naïve models exhibited a lack of significant effect on PD risk, both in each indi-
vidual cohort and when combined. Furthermore, models were constructed taking APOE ε4 status and patient 
sex into account, which again exhibited no significant association between TOMM40 ‘523’ genotype and PD 
risk. Models considering all combinations of ‘523’ and APOE ε genotypes also returned non-significant results. 
Binary logistic regression models were used subsequently to assess this association allelically. Neither naïve nor 
covariate corrected models, in either cohort or the combined cohort, exhibited a significant allelic association 
between TOMM40 ‘523’ and disease risk (Table 2). Finally, all models were repeated in the sub-cohort of APOE 
ε3/ε3 carriers (Supplementary Table 3), and again failed to show any significant associations between TOMM40 
‘523’ alleles or genotypes and risk of PD.
TOMM40 variant and age of disease onset. To investigate the influence of TOMM40 ‘523’ on age of 
disease onset, GLMs were constructed, with data from naïve and corrected models reported in Table 3. Within 
the Australian cohort, no significant association between TOMM40 ‘523’ alleles or genotypes and age of PD 
symptom onset was observed. However, in the PPMI cohort, carriage of the TOMM40 ‘523’ S/S genotype was 
Table 1.  Summary of the independent and combined cohort demographic information. Data presented as 
Mean (SD) or n (%). PPMI, Parkinson’s Progression Markers Initiative; PD, Parkinson’s disease.
Australian cohort PPMI cohort Combined cohort
PD Control PD Control PD Control
N 235 231 368 172 603 403
Male 150 (63.8) 147 (63.6) 241 (65.5) 113 (65.7) 391 (64.8) 260 (64.5)
Female 85 (36.2) 84 (36.4) 127 (34.5) 59 (34.3) 212 (35.2) 143 (35.5)
Age (years) 65.9 (9.4) 63.9 (12.5) 61.8 (9.6) 61.6 (10.5) 63.3 (9.7) 62.9 (11.7)
Symptom onset age (years) 57.3 (10.6) - 59.9 (9.7) - 58.9 (10.1) -
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associated with a 2.58 year later age of symptom onset (p = 0.040). This difference was not significant after control-
ling for APOE ε4 load and sex in multivariable GLMs, although a trend for later age of onset was still observable 
(1.970 years, p = 0.157). It is important to note, however, that there was a lack of co-carriage of the S/S genotype 
with the APOE ε4/ε4 genotype in this cohort (see Supplementary Table 4) and that APOE ε4/ε4 homozygotes 
had a mean age of symptom onset almost 4 years earlier than other genotypes, although this was not statisti-
cally significant (p = 0.314). Thus, significance may have been lost due to opposing directionalities of these two 
genotypes on age of symptom onset. Carriage of the S/S genotype was also associated with a 2.69 year later age 
of PD symptom onset in the PPMI cohort (p = 0.032) after correcting for APOE ε2 load and sex. However, when 
adjusting for multiple comparisons, model-derived estimated means revealed the S/S genotype did not result in 
a significantly different age of PD symptom onset when compared to individual genotypes (p = 0.326).
Subsequent analysis of the PPMI cohort exhibited no other statistically significant associations (at the 0.05 
level of significance), either allelically or genotypically. Furthermore, when the cohorts were analysed as a 
Figure 1.  Age of onset of PD symptom curves for TOMM40 ‘523’ genotypes. (A–C) indicate the age at which 
symptoms of PD began when stratified by TOMM40 ‘523’ genotype, as demonstrated by Kaplan–Meier curves. 
(C–E) indicate the age at which symptoms of PD began when stratified by TOMM40 ‘523’ and APOE genotype, 
as demonstrated by Kaplan–Meier curves. PPMI, Parkinson’s Progression Markers Initiative; S/S, short/short; 
S/L, short/long; S/VL, short/very long; L/L, long/long; L/VL, long/very long; VL/VL, very long/very long; S, 
short; L, long; VL, very long; ε2/ε2, Apolipoprotein epsilon 2/epsilon 2; ε2/ε3, Apolipoprotein epsilon 2/epsilon 
3; ε2/ε4, Apolipoprotein epsilon 2/epsilon 4; ε3/ε3, Apolipoprotein epsilon 3/epsilon 3; ε3/ε4, Apolipoprotein 
epsilon 3/epsilon 4; ε4/ε4, Apolipoprotein epsilon 4/epsilon 4.
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combined cohort, no significant associations were exhibited between TOMM40 ‘523’ and age of PD symptom 
onset (Table 3). Following this, all models were also repeated in the large sub-cohort consisting of only APOE 
ε3/ε3 homozygotes (Supplementary Table 5), none of which revealed a significant association between TOMM40 
‘523’ and age of symptom onset. Finally, when considering the load combination of the TOMM40 ‘523’ S allele 
and APOE ε4 or APOE ε2, no significant differences were found in the mean age of symptom onset between 
groups in either cohort or in the combined cohort according to the copy number of these alleles.
Kaplan–Meier curves for the age at which symptoms of PD were first reported were stratified by TOMM40 
‘523’ genotype, in the Australian cohort (Fig. 1A), the PPMI cohort (Fig. 1B) and the combined cohort (Fig. 1C). 
No or statistically significant or notable stratification was noted (p = 0.782, p = 0.321, p = 0.399), respectively. 
Subsequently, Kaplan–Meier curves for the age at which symptoms of PD began were analysed, stratified by 
Table 2.  Corrected regression models evaluating the association between ‘523’ genotype and disease risk in 
the two PD cohorts. + Data taken from Binary Logistic Regression models without correction for covariates. 
# Data taken from Binary Logistic Regression models with correction for APOE ε4 load and patient sex. P and 
OR (95% CI) values are calculated for the comparison to all other genotypes or alleles. PPMI, Parkinson’s 
Progression Markers Initiative; PD, Parkinson’s disease; OR, Odd’s Ratio; CI, confidence interval; p, statistical 
significance (p value); S/S, short/short; S/L, short/long; S/VL, short/very long; L/L, long/long; L/VL, long/very 
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Table 3.  Generalised linear model investigating association between TOMM40 ‘523’ and age of PD symptom 
onset in the Australian and PPMI cohorts. + Data taken from GLM without correction for covariates. # Data 
taken from GLMs corrected for APOE ε4 load and patient sex. P and β-CoE values are calculated for the 
comparison to all other genotypes or alleles. PPMI, Parkinson’s Progression Markers Initiative; PD, Parkinson’s 
disease; β-CoE, β-Coefficient; p, statistical significance (p value); S/S, short/short; S/L, short/long; S/VL, short/
very long; L/L, long/long; L/VL, long/very long; VL/VL, very long/very long; S, short; L, long; VL, very long; 








Naïve+ Corrected# Naïve+ Corrected# Naïve+ Corrected#
β-CoE p β-CoE p β-CoE p β-CoE p β-CoE p β-CoE p
S/S −2.008 .267 −1.388 .469 2.580 .040 1.970 .157 0.957 .361 0.728 .525
S/L −2.222 .331 −1.935 .538 −2.460 .129 −2.759 .181 −2.355 .078 −2.464 .160
S/VL 0.816 .569 1.354 .424 −1.228 .235 −1.301 .259 −0.487 .566 −0.455 .638
L/L 3.399 .403 4.142 .715 0.312 .956 10.474 .214 1.602 .620 8.047 .156
L/VL 1.417 .551 1.717 .583 0.131 .941 1.967 .364 0.587 .682 1.131 .520
VL/VL 0.646 .732 −0.482 .821 0.653 .607 0.082 .952 0.770 .470 0.159 .892
S −1.261 .416 0.088 .960 −0.561 .613 −0.903 .458 −0.838 .358 −0.631 .536
L 0.087 .958 0.644 .932 −1.149 .338 0.647 .812 −0.687 .485 0.375 .887
VL 1.887 .209 1.480 .370 −0.824 .448 −0.689 .552 0.227 .799 −0.004 .997
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TOMM40 ‘523’ and APOE genotype as in Roses et al.13. Again, neither the Australian cohort (p = 0.550, Fig. 1D), 
or the PPMI cohort (p = 0.867, Fig. 1E), or the combined cohort (p = 0.660, Fig. 1F) exhibited statistically strati-
fied ages of PD symptom onset. Kaplan–Meier analysis based on TOMM40 ‘523’ allelic stratification also failed 
to produce significant results. Finally, all analyses completed using the Kaplan–Meier method were re-run using 
Cox proportional hazard regression models, which adjusted for sex, and no significant results were noted.
Discussion
The current study aimed to investigate the TOMM40 ‘523’ structural variant as a potential PD risk factor and 
modifier of the age at symptom onset. The distribution of ‘523’ poly-T alleles did not vary between PwP and 
healthy controls, or in the two independent cohorts examined. The similarity in ‘523’ allelic distribution between 
the PPMI and Australian cohorts is worth noting as this study utilised two different approaches in the calling of 
the TOMM40 ‘523’ variant, establishing a PCR-based and a WGS-based assay for use in the Australian and PPMI 
cohorts, respectively. Assay development for the TOMM40 ‘523’ variant is generally considered to be difficult, 
as poly-T variants are challenging to  sequence13,19. Despite optimisation within this study, PCR stuttering was 
observed in the PCR-based assay similar to previous  reports13,19, which is a standard complication when amplify-
ing repetitive genomic sequences, and highlights the need for further optimisation of the assay. By comparison, 
calling from WGS files revealed a similar distribution as reported  previously33. While it has been presented as 
having fewer challenges in optimisation and sequencing, calling of ‘523’ variants was an arduous process and 
the aforementioned study has stated that the correlation between ‘523’ calling by WGS and PCR-based methods 
decreases with increasing size of the ‘523’  allele33.
The present study then examined whether the TOMM40 ‘523’ variant is implicated in PD risk and found 
no association between carriage of allelic variants and the risk of developing PD. When binned, genotypic and 
allelic frequencies appeared to be similar between controls and PwP in both independent cohorts, and when 
the cohorts were combined. This agrees with previous work in a Polish PD cohort which showed no association 
of ‘523’ alleles, genotypes or haplotypes with the risk of PD or age of symptom  onset27. In contrast, in a Swedish 
population, a higher frequency of the L/VL genotype was observed in PD patients compared to  controls28, though 
these findings are yet to be published in full. Given that these studies were conducted in different ethnic groups, 
and that ‘523’ allele frequencies are ethnic-specific18, the contradictory findings in the studies to date may indicate 
that ‘523’ is a risk factor in some populations, but not in others. As this is only the third study to investigate the 
role of TOMM40 ‘523’ in PD risk, further studies should be performed in other ethnically diverse populations.
As mitochondrial involvement in PD is thought to be a key contributor to neuronal dysfunction and degenera-
tion, it is plausible that a genetic variant that modulates mitochondrial function could modify age of symptom 
onset. Furthermore, AD and PD share a number of clinical, pathological and molecular features including toxic 
protein accumulation and mitochondrial dysfunction in the form of respiratory chain defects, oxidative stress, 
mitochondrial DNA damage and morphological  abnormalities5,38,39. Previous studies have implicated TOMM40 
‘523’ length in the age of onset of AD, particularly in carriers of the APOE ε3  allele9,22, but mixed findings exist. 
For instance, although Roses et al.9 reported that longer ‘523’ allele lengths were associated with risk of AD and 
earlier age of onset, the initial findings were not replicated in other  populations22,40. Such varied findings may 
be a result of varied methodology and varied consideration of the influence of the APOE ε  locus13, which is 
well-established as the strongest genetic predictor of AD. Most studies to date report no association of APOE ε 
variation with susceptibility to  PD41,42, as was also the case in the current study. While the present findings did 
not show any positive evidence of interactive effects between TOMM40 ‘523’ and APOE ε genotypes in relation to 
PD risk, they do suggest that the two loci may have small independent and opposing effects on determining the 
age of onset of the symptoms. While initial regression analyses in the PPMI cohort showed that age of onset was 
significantly delayed by carriage of the S/S ‘523’ genotype, this was not replicated after correction for covariates, 
or in the Australian cohort. However, it is possible that this difference is caused by a country- or geographical-
specific effect, as seen in other genetic  studies43. It is worth noting that only one prior study has examined this 
 association27, though it is not clear whether this study completed rigorous analysis of the interactive effects of 
TOMM40 and APOE, as was conducted in the current study. As such, further in-depth analysis in larger PD 
cohorts is required to determine the significance of the present findings.
Currently, the functional effects of variation in ‘523’ allele length are poorly understood due to a scarcity 
of research in this area. While several studies have suggested that the VL allele increases TOMM40 mRNA 
expression and the S allele represses  expression12,19,20,44, others have found no significant differences in mRNA 
levels between S and VL  variants45. A recent study demonstrated that overexpression of TOMM40 in vitro was 
associated with greater mitochondrial membrane potentials, respiratory rates, spare respiratory capacities, ATP 
levels, amyloid-beta resistance, and protein  uptake16. On the other hand, another study observed a correlation 
between TOM40 protein deficits and enhanced oxidative stress, reduced ATP production and abnormal complex 
I protein concentrations in the brains of PD patients and in alpha-synuclein overexpressing murine  models21. 
As the literature currently stands, further elucidation of the biological consequences of up- or down-regulated 
TOMM40 expression is required to give insight into its potential role in PD risk and disease modification.
Conclusion
Overall, this study aimed to investigate the risk and disease-modifying role of the TOMM40 ‘523’ variant in two 
independent PD cohorts. TOMM40 plays an essential role in mitochondrial import and mitophagy, and the 
‘523’ polymorphism has been associated with age of onset of AD and with age-related cognitive decline. While 
this study clarifies that TOMM40 ‘523’ is not in itself a predictor of PD risk, it raises the possibility that, as in 
AD, it may be a genetic marker for the age of symptom onset in PD. Whilst not conclusive, our findings in the 
large international PPMI cohort suggest that carriage of the S/S ‘523’ genotype may be protective in terms of 
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delaying the age of symptom onset, and may warrant further investigation in other populations. Importantly, 
the effect of co-carriage of the APOE ε4 allele, which appears to have an opposing effect on age of onset, must 
be considered in future studies. Though not significant in modulating risk of PD, future studies should consider 
the possible role of TOMM40 ‘523’as a determinant of age of symptom onset, and symptom trajectory. Given a 
phase 3 clinical trial of a therapeutic for the prevention and delay of onset of AD was recently conducted involv-
ing participants stratified by TOMM40 ‘523’46, the findings reported herein are noteworthy, and may allow the 
design of symptom-focused studies in PD for much-needed improvements in patient outcomes and care.
Data availability
Any data pertaining to this article and not published within this article may be requested through collaboration.
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